November 8, 2017 Toulouse, FRANCE, Lakeland, UNITED STATES, CERENIS Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, today announces the acquisition of LYPRO Biosciences assets, a portfolio of proprietary drug delivery nanotechnology. The operation positions CERENIS at the forefront of the chemotherapy drug delivery and immuno-oncology space. This represents a significant step towards the Company’sstrategic objective of developing the next generation of multiple targeted drug delivery nanotechnologies associated with HDL therapy.